White House science adviser responds to inquiry regarding handling of H5N1 research controversy

NewsGuard 100/100 Score

"White House science adviser John Holdren has replied [.pdf] to questions asked last month by Representative Jim Sensenbrenner (R-Wisc.) about how the Obama Administration has handled the controversy surrounding two studies that showed how to make the H5N1 avian influenza virus transmissible between mammals," ScienceInsider reports. On March 1, "Sensenbrenner -- a former head of the House of Representatives committees on science and the judiciary, and currently vice chair of the House Committee on Science, Space, and Technology, sent a 'fact-finding letter' [.pdf] to Holdren" asking a "number of questions about how the government reviews potential 'dual-use research of concern' (DURC) that might be used for good or evil," the news service writes.

In his April 9 response, "Holdren wrote that 'the circumstances surrounding the recent review of H5N1 manuscripts are unprecedented. ... Thus, the (U.S. government) until now had not needed to have a system in place specifically for restricting dissemination of the results of DURC,'" the news service notes, adding, "The government has issued a new policy for reviewing taxpayer-funded research for DURC potential, he noted." The news service continues, "In a statement, Sensenbrenner said he was only partly satisfied," writing, "I believe the Administration needs to be more proactive than that and prepare for possible threats before they occur. The new policy is a good, if belated, first step, and I will be watching its implementation closely" (Malakoff, 4/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis